New drug for duchenne under Real-World watch: safety first
Disease control
Recruiting now
This study follows about 300 people with Duchenne muscular dystrophy who are taking the drug givinostat as part of their regular care. Researchers will track side effects like low platelet counts and bleeding, as well as how well the drug works over up to 5 years. The goal is to …
Sponsor: ITF Therapeutics LLC • Aim: Disease control
Last updated May 11, 2026 20:38 UTC